175 Million Europeans Have Sleep Apnoea, Highlighting Scale of Global Health Crisis
September 18 2018 - 09:05AM
Business Wire
Late-breaking abstract at ERS Congress provides
new estimate from leading researchers and key opinion leaders
Roughly 175 million Europeans have obstructive sleep apnoea,
according to a late-breaking abstract presented by ResMed today at
the European Respiratory Society’s annual ERS Congress in Paris.
Leading researchers estimate 90 million Europeans have moderate to
severe sleep apnoea, meaning they experience at least 15 breathing
events an hour during sleep.
These statistics are based on the latest scoring rules for
determining one’s apnoea–hypopnoea index (AASM 2012) and are
connected with a 16-country study announced in May 2018 that
revealed an estimated 936 million people worldwide have sleep
apnoea, a chronic sleep-disordered breathing condition associated
with increased risk of mortality and reduced quality of life.
The new global prevalence is nearly tenfold higher than the
previous one – 100 million – estimated by the World Health
Organization in 2007.
European countries with the highest prevalence are:
- Russia, 40 million
- Germany, 26 million
- France, 24 million
- Ukraine, 13 million
- Spain, 9 million
- United Kingdom, 8 million
“This data is a warning call to Europe’s doctors and other care
providers to properly identify, screen and diagnose these people so
they can get the life-changing treatment they need,” said Dr. Adam
Benjafield, lead researcher and ResMed’s vice president of Medical
Affairs.
Benjafield said one sign of an at-risk patient is whether they
have a related chronic medical condition:
- 83% of people with drug-resistant
hypertension have sleep apnoea
- 77% of people with obesity
- 76% of people with chronic heart
failure
- 72% of people with type 2 diabetes
- 62% of people with a prior stroke
- 49% of people with atrial
fibrillation
“Doctors should screen their patients if they have any of these
conditions,” said Benjafield, “especially if a patient has
exhibited sleep apnoea-related symptoms like snoring, daytime
sleepiness or frequent nighttime urination.”
About ResMed
ResMed (NYSE: RMD) (ASX: RMD), a world-leading connected health
company with more than 5 million cloud-connected devices for daily
remote patient monitoring, changes lives with every breath. Its
award-winning devices and software solutions help treat and manage
sleep apnoea, chronic obstructive pulmonary disease and other
respiratory conditions. Its 6,000-member team strives to improve
patients’ quality of life, reduce the impact of chronic disease and
save healthcare costs in more than 120 countries. ResMed.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180918005278/en/
ResMedFor media:Jayme Rubenstein+1
858.836.6798news@resmed.comorFor investors:Amy Wakeham+1
858.836.5000investorrelations@resmed.com
ResMed (NYSE:RMD)
Historical Stock Chart
From Feb 2024 to Mar 2024
ResMed (NYSE:RMD)
Historical Stock Chart
From Mar 2023 to Mar 2024